Commentary: The top ten reasons to limit prescription of controlled substances in prisons

Journal of the American Academy of Psychiatry and the Law

Volumn 37, Issue 1, 2009, Pages 50-52

  Burns, Kathryn A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CENTRAL STIMULANT AGENT;

ATTENTION DEFICIT DISORDER; DISEASE CONTROL; HUMAN; MEDICAL STAFF; MENTAL HEALTH; NOTE; POPULATION; PRESCRIPTION; PREVALENCE; PRISON; SUBSTANCE ABUSE; ADDICTION; ARTICLE; CLINICAL PROTOCOL; PRISONER; PSYCHOLOGICAL ASPECT; UNITED STATES;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL PROTOCOLS; HUMANS; MASSACHUSETTS; PRISONERS; SUBSTANCE-RELATED DISORDERS;

EID: 66149108015     PISSN: 10936793     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Appelbaum KL: Attention deficit hyperactivity disorder in prison: a treatment protocol. J Am Acad Psychiatry Law 37:45-9, 2009
2. American Psychiatric Association: Psychiatric Services in Jails and Prisons (ed 2). Washington, DC: American Psychiatric Association, 2000
3. Adler LA, Newcorn JH, Spencer TJ, et al.: Best practices in adult ADHD: special considerations. CNS Spectr Suppl 13(Suppl 15): 1-16, 2008
4. California Dept. of Corrections and Rehabilitation formulary: Available at: www.cphcs.ca.gov/docs/projects/CDCR-Formulary-200810.pdf. Accessed October 2008
5. Burns KA: Psychopharmacology in correctional settings, in Clinical Handbook of Correctional Psychiatry. Edited by Scott C. Washington, DC: American Psychiatric Press, 2005, pp 89-108